Loading...
Loading...
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd.. Spoken Alpha tracks NRSNW's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks NRSNW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRSNW.
curl https://api.spokenalpha.com/v1/companies/NRSNW| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.87 | $1.79 | +4.4% | -0.1% | +0.6% |
| Q4 FY2026 | $1.83 | $1.79 | +2.1% | +2.3% | 0.0% |
| Q3 FY2026 | $1.61 | $1.60 | +0.5% | -1.4% | -0.6% |
| Q2 FY2026 | $1.90 | $1.73 | +10.1% | +4.9% | +3.2% |
| Q1 FY2025 | $1.83 | $1.79 | +2.5% | +0.1% | +0.3% |
| Q4 FY2025 | $1.84 | $1.64 | +12.3% | +2.2% | +1.7% |
| Q3 FY2025 | $1.93 | $1.68 | +14.7% | -1.4% | -0.9% |
| Q2 FY2025 | $1.93 | $1.68 | +14.9% | +3.3% | +5.6% |
| Q1 FY2024 | $2.21 | $1.96 | +12.6% | -0.1% | +2.0% |
| Q4 FY2024 | $2.18 | $1.94 | +12.6% | -1.6% | -1.0% |